Thursday, November 5, 2026

DAX Bearish Momentum: 1.44% Down Since The Last Session

ViaNews Editorial Team

January 15, 2021

DAX Bearish Momentum: 1.44% Down Since The Last Session

DAX is currently on bearish momentum. At 14:27 EST on Friday, 15 January, DAX is at €13,787.73, 1.44% down since the last session's close.

DAX Range

DAX is 1.113% down from its last session low of €13,942.90 and 1.728% down from its last session high of €14,030.20.

Over the last three sessions, DAX's higher value was €14,030.20 and the lower value was €13,868.80.

Over the last seven sessions, DAX's higher value was €14,131.50 and the lower value was €13,617.10.

Over the last month, DAX's higher value was €14,131.50 and the lower value was €13,009.50.

Concerning DAX's yearly highs and lows, it's 67.01% up from its 52-week low and 2.433% down from its 52-week high.

Volatility

DAX's last day, last week, and last month's average volatility was 0.35%, 0.03%, and 0.24%, respectively.

DAX's last day, last week, and last month's high and low average amplitude percentage was 0.63%, 0.94%, and 1.19%, respectively.

Last news about DAX

DAX 30 poised to extend climb despite threat of extended restrictions. According to DailyFX on Thursday, 14 January, "Nevertheless, a degree of caution should be maintained in the near term as the reality of a prolonged period of harsh curbs may begin to gnaw at risk appetite and in turn weigh on Germany's benchmark DAX 30 index.", "We typically take a contrarian view to crowd sentiment, and the fact traders are net-short suggests DAX 30 prices may continue to rise."

DAX falls on virus worries. According to Business Insider on Friday, 15 January, "The benchmark DAX dropped 36 points, or 0.3 percent, to 13,952 after rising 0.4 percent the previous day."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com